SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older
Phase 3
Completed
- Conditions
- DiphtheriaTetanusPoliomyelitisPertussis
- Interventions
- Biological: Diphtheria, tetanus, polio and pertussis vaccination
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 342
- Registration Number
- NCT01287949
- Locations
- 🇩🇪
Sanofi Pasteur MSD investigational site, Rodgau, Germany
A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China
Phase 4
Completed
- Conditions
- PolioPoliomyelitis
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 5007
- Registration Number
- NCT01278433
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Phase 4
Completed
- Conditions
- Meningococcal DiseaseMeningitis
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 538
- Registration Number
- NCT01270503
A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: High-Dose Trivalent Inactivated Influenza VaccineBiological: Trivalent Inactivated Influenza Vaccine
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 300
- Registration Number
- NCT01258595
Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old
Phase 3
Completed
- Conditions
- TetanusPertussisDiphtheriaPoliomyelitis
- Interventions
- Biological: Concomitant administrationBiological: Separate administration
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 954
- Registration Number
- NCT01249183
- Locations
- 🇩🇪
Sanofi Pasteur MSD Investigational Site, Reichenbach, Germany
Study of Quadrivalent Influenza Vaccine Among Children
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Quadrivalent Influenza Vaccine, No PreservativeBiological: Investigational Trivalent Influenza Vaccine with alternate B strain, No PreservativeBiological: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 4363
- Registration Number
- NCT01240746
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Phase 2
Completed
- Conditions
- Clostridium Difficile InfectionDiarrhea
- Interventions
- Biological: Clostridium difficile toxoids A and B (Low-dose without adjuvant)Biological: Clostridium difficile toxoids A and B (high-dose with adjuvant)Biological: Clostridium difficile toxoids A and B (Low-dose with adjuvant)Biological: Clostridium difficile toxoids A and B (high-dose without adjuvant)
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 650
- Registration Number
- NCT01230957
Study of Quadrivalent Influenza Vaccine Among Adults
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Investigational Quadrivalent Inactivated Influenza Vaccine, No PreservativeBiological: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2013-10-23
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 739
- Registration Number
- NCT01218646
Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea
Phase 4
Completed
- Conditions
- Influenza
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 240
- Registration Number
- NCT01215669
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
Phase 3
Completed
- Conditions
- VaricellaJapanese Encephalitis
- Interventions
- Biological: Varicella VaccineBiological: JE-CV Vaccine
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 454
- Registration Number
- NCT01190228
© Copyright 2025. All Rights Reserved by MedPath